GURUFOCUS.COM » STOCK LIST » USA » NAS » Grifols SA (NAS:GRFS) » Definitions » Forward PE Ratio
Switch to:

Grifols Forward PE Ratio

: 27.25 (As of Today)
View and export this data going back to 2011. Start your Free Trial

Grifols's Forward PE Ratio for today is 27.25.

Grifols's PE Ratio without NRI for today is 105.81.

Grifols's PE Ratio for today is 105.81.


Grifols Forward PE Ratio Historical Data

The historical data trend for Grifols's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data
Trend 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 2022-08
Forward PE Ratio
15.70 14.95 15.90 14.93 18.55 13.05 8.84 20.37

Grifols Quarterly Data
2015-12 2016-03 2016-06 2016-09 2016-12 2017-03 2017-06 2017-09 2017-12 2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06
Forward PE Ratio 15.70 10.03 15.02 14.47 14.95 16.64 17.79 14.93 15.90 15.77 18.87 15.63 14.93 15.22 16.72 16.42 18.55 16.39 14.95 10.29 13.05 11.78 12.90 10.66 8.84 8.82 20.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Grifols Forward PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's Forward PE Ratio falls into.



Grifols Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Grifols  (NAS:GRFS) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Grifols Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Grifols's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols Business Description

Grifols logo
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 15% of revenue following the Novartis and Hologic deals.

Grifols Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)